|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD
21.51 Billion
|
|
CAGR (2025-2030)
|
6.27%
|
|
Fastest Growing Segment
|
Contact Lens
|
|
Largest Market
|
Germany
|
|
Market Size (2030)
|
USD 31.05 Billion
|
Market Overview
Europe Eye Care Market was valued at USD
21.51 Billion in 2024 and is expected to reach USD 31.05 Billion by 2030,
growing with a CAGR of 6.27% in the forecast period. The Europe eye care market
is witnessing steady growth, driven by an aging population, rising incidence of
eye-related disorders, and increasing awareness about eye health. With
age-related conditions such as macular degeneration, cataracts, and glaucoma
becoming more prevalent, demand for both corrective and preventive eye care
solutions is on the rise. Additionally, the surge in screen time due to
digitalization across work and lifestyle settings is contributing to a growing
need for vision correction products, particularly among younger demographics. The
market encompasses a broad spectrum of products and services, including
prescription eyewear (glasses and contact lenses), surgical procedures,
diagnostics, pharmaceuticals, and over-the-counter (OTC) eye drops. Among
these, the prescription segment continues to dominate in terms of revenue,
while OTC products are gaining significant traction owing to increased consumer
preference for self-medication and convenience. The shift toward personalized
and fashion-oriented eyewear also supports the growth of premium optical
solutions in the region.
Technological innovation plays a
critical role in shaping the competitive landscape of the European eye care
market. Advanced diagnostic tools, minimally invasive surgeries, and AI-based
retinal screening systems are improving the quality of patient care and
operational efficiency across ophthalmology clinics and hospitals. The
integration of telemedicine for remote eye examinations is another trend
gaining momentum, especially in post-pandemic healthcare delivery models. From
a country-specific perspective, Germany, France, and the UK hold substantial
shares in the regional market, supported by robust healthcare infrastructure
and high consumer spending. However, emerging economies in Eastern Europe are
expected to offer untapped opportunities, fueled by improving healthcare access
and expanding urban middle-class populations.
Key Market Drivers
Increased
Screen Time and Digital Eye Strain is Driving Europe's Eye Care Market
The Europe eye care market is
experiencing significant growth, driven primarily by the surge in screen time
and the rising prevalence of digital eye strain (DES). With the accelerated
adoption of digital technologies in both professional and personal settings,
the region is witnessing a notable shift in consumer behavior and healthcare
needs, particularly concerning eye health. The increasing reliance on digital
devices—such as smartphones, laptops, tablets, and televisions—has become an
integral part of modern lifestyles across Europe. Post-pandemic work-from-home
models, online learning, and streaming entertainment have led to prolonged
exposure to digital screens. According to recent surveys, European adults spend
an average of 6 to 8 hours per day on digital devices, with younger
demographics often exceeding that threshold. This growing screen dependency has
escalated the incidence of digital eye strain, also referred to as computer
vision syndrome. As per the survey published by Elsevier in December
2024, titled "Digital Eye Strain and Its Impact on Working Adults in
the UK and Ireland," a high prevalence of Digital Eye Strain (DES) was
observed, with 62.6% of respondents scoring ≥6 on the Computer Vision Syndrome
Questionnaire. On average, individuals reported using digital devices for 9.7
hours per day. Musculoskeletal symptoms were experienced by 94.3% of
participants, while 89.5% reported ocular symptoms, with a higher incidence
among those working from home. Additionally, 8.1% of respondents indicated that
their symptoms were severe enough to negatively impact their work performance.
Digital eye strain is characterized by
symptoms such as dry eyes, blurred vision, headaches, and eye
fatigue—conditions that are increasingly prompting consumers to seek medical
advice and over-the-counter remedies. As a result, there is a marked uptick in
the demand for lubricating eye drops, anti-reflective lenses, blue light
filtering eyewear, and nutritional supplements targeting ocular health. These
products have become essential components of daily wellness routines,
particularly for working professionals and students.
The growing prevalence of digital eye
strain presents a lucrative opportunity for eye care companies across Europe.
Pharmaceutical firms, optical retailers, and vision care providers are
expanding their product portfolios to address this emerging health concern.
Innovative solutions, such as digitally optimized prescription lenses and
artificial tears designed for prolonged screen exposure, are gaining traction
in the market. In response, several companies are investing in research and
development to introduce clinically-backed, fast-acting formulations that offer
relief from digital fatigue. Additionally, educational campaigns promoting eye
health awareness and the importance of regular eye checkups are being launched
to reinforce brand engagement and consumer trust.
Europe’s aging population further
contributes to market growth, as older individuals are more susceptible to
vision-related issues, including age-related macular degeneration and
presbyopia. According to Eurostat, nearly 21.6% of the EU population was aged 65
years or older in 2023.
Moreover, favorable reimbursement policies in countries like Germany, France,
and the Netherlands support access to ophthalmic care, boosting market
penetration. At the same time, regulatory support for digital health solutions,
including tele-optometry and AI-enabled diagnostics, is streamlining the
patient journey and expanding access to care in underserved regions.
Ageing
Population and Rising Prevalence of Vision Disorders
The Europe eye care market is undergoing
a significant transformation, driven primarily by demographic changes and
increasing vision-related health concerns. One of the most influential factors
contributing to this growth is the ageing population across the region. As the
median age continues to rise, so does the demand for comprehensive eye care
solutions—including diagnostics, treatment, and corrective products—fueling
both innovation and expansion within the industry. Europe is among the most
rapidly ageing regions globally. According to Eurostat, in 2023, over one-third (35.0%)
of individuals in the European Union reported living with a long-standing
(chronic) health condition. Ageing
is intrinsically linked to a higher risk of developing vision disorders such as
cataracts, age-related macular degeneration (AMD), glaucoma, and diabetic
retinopathy. These conditions require early diagnosis, continuous monitoring,
and long-term management—driving increased utilization of ophthalmic devices,
specialty pharmaceuticals, and vision correction solutions.
In addition to natural ageing, the
growing incidence of chronic diseases such as diabetes and hypertension is also
accelerating the prevalence of vision disorders. Diabetic retinopathy, for
example, is now one of the leading causes of blindness among working-age adults
in Europe. The need for specialized diagnostic imaging equipment and targeted
therapeutics has seen a marked uptick, further boosting demand across the eye
care continuum. With demand rising, companies operating in the Europe eye care
market are focusing on product innovation and expanding accessibility. There is
a growing emphasis on minimally invasive surgical techniques, advanced
intraocular lenses (IOLs), and teleophthalmology solutions to address both
urban and rural healthcare disparities. Moreover, the increasing use of
artificial intelligence in retinal screening and diagnostics is enabling early
detection and timely intervention, especially for high-risk elderly populations.
The demand for vision correction
products—such as prescription eyeglasses, contact lenses, and refractive
surgery—is also experiencing robust growth. Progressive lenses and daily
disposable contact lenses are particularly gaining traction among older adults
seeking both convenience and performance. In parallel, the cosmetic appeal and
technological enhancements of eyewear are drawing a wider customer base,
further driving market penetration. European healthcare systems, known for
their comprehensive coverage, are also contributing to market momentum. Public
health initiatives encouraging routine eye examinations and subsidized
treatment options for the elderly are improving early diagnosis rates.
Additionally, collaborative efforts between governments and private players are
fostering a conducive environment for research, innovation, and market entry
for new eye care products.
Download Free Sample Report
Key Market Challenges
Price
Sensitivity and Reimbursement Pressures
Public healthcare systems across Europe
are under increasing financial strain, leading to tighter reimbursement
policies for vision care services and products. In many countries, essential
products such as intraocular lenses, contact lenses, and prescription eye drops
are subject to price caps or limited reimbursement, directly impacting margins.
Moreover, out-of-pocket costs for patients often influence purchasing
decisions, particularly in price-sensitive markets like Eastern Europe, where
private spending is lower.
Key Market Trends
Technological
Advancements and Innovation
The Europe eye care market is undergoing
a transformative phase, driven by rapid technological advancements and
sustained innovation. From diagnostics to treatment and post-operative care,
the sector is witnessing a shift towards more precise, efficient, and
patient-centric solutions. As the region grapples with a growing prevalence of
ophthalmic conditions such as age-related macular degeneration (AMD), diabetic
retinopathy, glaucoma, and refractive errors, the demand for advanced
technologies is rising significantly.
Artificial intelligence (AI) and machine
learning are increasingly being integrated into diagnostic systems, enabling
early detection and continuous monitoring of complex eye disorders. AI-powered
retinal imaging and optical coherence tomography (OCT) tools are enhancing
diagnostic accuracy and enabling ophthalmologists to make informed decisions
faster. Startups and established companies across Europe are investing in these
technologies, leveraging data analytics to identify patterns that traditional diagnostics
may miss.
Digital platforms are also
revolutionizing eye screenings through mobile apps and teleophthalmology
services, particularly benefiting rural and underserved areas. These
innovations support broader access to eye care while optimizing clinic
workflows and reducing the burden on healthcare professionals. Technological
progress in surgical procedures is another major growth driver. The development
of minimally invasive techniques, such as femtosecond laser-assisted cataract
surgery and small-incision lenticule extraction (SMILE), is improving patient
outcomes and recovery times. Laser-based vision correction technologies
continue to evolve, offering safer and more effective options for patients with
myopia, hyperopia, and astigmatism.
Europe-based manufacturers and medical
device companies are focusing on developing next-generation laser platforms and
robotic-assisted surgical tools, which are gaining regulatory approvals and
market traction across the region. Another noteworthy trend is the rise of
smart eye care wearables and personalized solutions. Smart contact lenses with
biosensing capabilities are in development, offering possibilities such as
intraocular pressure monitoring for glaucoma patients. Additionally, advances
in lens materials and design are enabling the customization of corrective
lenses to meet specific user needs, particularly for presbyopia and digital eye
strain—conditions becoming increasingly common in the digital age. In the
pharmaceutical segment, innovation is focused on sustained-release drug
delivery systems, reducing the frequency of intravitreal injections for chronic
conditions like AMD and diabetic macular edema. European biotech firms and
research institutions are collaborating to bring novel ophthalmic drugs and
gene therapies to market. These therapies aim to address underlying genetic
causes and offer long-term benefits, marking a shift from symptomatic treatment
to disease modification..
Segmental Insights
Product
Type Insights
Based on the category of Product Type, the
contact lens segment had the highest share of revenue in 2024. One of the most
significant factors is the rising prevalence of refractive errors across the
European population. Conditions such as myopia (nearsightedness), hyperopia
(farsightedness), astigmatism, and presbyopia are increasingly common,
particularly among young adults and the aging population. Contact lenses offer
a highly effective, flexible, and non-surgical solution for managing these
vision issues. Their discreet and convenient use appeals to a wide demographic,
especially individuals who prefer alternatives to traditional eyeglasses. Additionally,
advancements in lens technology have made contact lenses more comfortable and
versatile. Innovations such as silicone hydrogel lenses, daily disposables,
extended wear lenses, and lenses designed for dry or sensitive eyes have
expanded the user base. Multifocal and toric lenses, which cater to complex
vision problems like presbyopia and astigmatism, further increase market
appeal. Moreover, specialty lenses that offer UV protection or filter blue
light have gained popularity due to growing awareness about eye strain caused
by screen time.
Lens
Material Insights
Based on the category of Lens Material, the
Normal Glass segment secured the largest share of revenue in 2024,owing to a
combination of functional, economic, and demographic factors. Despite the
increasing popularity of advanced lens materials such as polycarbonate and
high-index plastics, normal glass lenses retained a significant share due to
their optical clarity, durability, and cost-effectiveness. These lenses
continue to offer superior resistance to scratches and provide exceptional
vision correction, especially for individuals with high prescriptions, where
distortion can be a concern with plastic lenses.
Another key reason behind the strong
performance of the normal glass segment is its established use among older
populations, who form a major consumer base in Europe’s eye care sector. Older
patients often prefer traditional materials they are familiar with, and many
opticians continue to recommend glass lenses for their refractive stability and
long-lasting performance. This segment also benefits from a loyal consumer
group that values the premium feel and aesthetic clarity that glass lenses
offer. Sustainability considerations and eco-conscious choices are gaining
traction across Europe. Normal glass is perceived as a more environmentally
friendly option compared to synthetic polymers, as it is made from natural
materials and is more easily recyclable. This aligns with the region's strong
push for green and sustainable healthcare practices, especially in countries
like Germany, France, and the Netherlands.
Download Free Sample Report
Regional Insights
In 2024, Germany held the largest market
share in terms of revenue. One of the most significant drivers is its aging
population. With a substantial percentage of citizens aged 65 and above, there
is a naturally high demand for eye care services and products. Germany is
currently among the five "super-aged" societies globally, with
individuals aged 65 and above comprising a significant portion of its
population. This demographic segment is expected to expand further, projected
to account for nearly one-third of the country's total population by 2050. Age-related conditions such
as cataracts, macular degeneration, and presbyopia are becoming increasingly
common, necessitating regular eye examinations, corrective lenses, and surgical
interventions—all of which contribute to high market revenues. Germany also
benefits from a highly developed healthcare system that prioritizes preventive
care and early intervention. The accessibility of healthcare services across
urban and rural areas has made it easier for patients to seek timely treatment
for eye-related conditions. Moreover, routine eye checkups are widely promoted
through insurance-backed programs, increasing the demand for both
over-the-counter and prescription-based eye care solutions.
Recent Developments
- In June 2025, Johnson & Johnson announced the
expansion of its presbyopia-correcting intraocular lens (PC-IOL) portfolio with
the launch of the TECNIS Odyssey IOL across Europe, the Middle East, and
Canada. This next-generation intraocular lens provides a full range of
high-quality, continuous vision, enabling patients to see clearly at near,
intermediate, and far distances—significantly reducing their dependence on
glasses. Developed on the industry-leading TECNIS platform, the TECNIS Odyssey
IOL combines advanced optical technology with proprietary materials to deliver
consistently clear, high-contrast vision.
- In June 2025, Santen Pharmaceutical Co., Ltd.
announced that it had received marketing authorisation from the European
Commission (EC) for its 0.1 mg/mL atropine eye drop. The low-dose formulation,
branded as Ryjunea, has been licensed from California-based Sydnexis
Inc. to Santen SA, headquartered in Switzerland. Earlier, in April 2025, the
European Medicines Agency (EMA) and its Committee for Medicinal Products for
Human Use (CHMP) issued a positive opinion supporting the use of the atropine
eye drop as a treatment for paediatric myopia.
- In October 2024, Novaliq, a biopharmaceutical company
specializing in first- and best-in-class ocular therapeutics based on its
proprietary EyeSol water-free technology, and Laboratoires Théa (Théa),
Europe’s leading independent eye care group, announced that the European
Commission has approved Vevizye (ciclosporin 0.1% eye drops solution) for use
in Europe. Concurrently, the two companies finalized a partnership agreement
granting Théa the exclusive rights to commercialize Vevizye across Europe and
select countries in the Middle East and North Africa (MENA) region.
- In June 2024, Ikerian AG—a medical software company
headquartered in both Bern, Switzerland, and Boston, Massachusetts—announced an
update on four of its devices. The company received a Class IIa medical device
certification under the European Union Medical Device Regulation (EU MDR) for
its AI-driven platform, RetinAI Discovery. This platform utilizes artificial
intelligence modules to identify and quantify retinal biomarkers, supporting
fluid and layer segmentation. These diagnostic capabilities are designed to
assist in the detection and monitoring of retinal diseases.
Key Market Players
- Novartis
AG
- Essilor International SA
- F.Hoffmann-La Roche
- Alcon Laboratories UK Ltd
- Allergan, Ltd.
- Johnson & Johnson Vision
Care Ireland Ltd
- Hoya Lens UK Ltd.
- Bausch & Lomb GmbH
- Abbott (UK) Holdings Ltd.
- Carl Zeiss Meditec AG
|
By Product Type
|
By Coating
|
By Lens Material
|
By Distribution
Channel
|
By Country
|
- Eyeglasses
- Contact Lens
- Intraocular Lens
- Eye Drops
- Others
|
- Anti-Glare
- Anti-Reflecting
- Others
|
- Normal Glass
- Polycarbonate
- Trivex
- Others
|
- Retail Stores
- E-Commerce
- Clinics
- Hospitals
|
- Germany
- France
- United Kingdom
- Italy
- Spain
- Switzerland
- Netherlands
- Turkey
- Sweden
- Belgium
|
Report Scope:
In this report, the Europe Eye Care Market has been
segmented into the following categories, in addition to the industry trends
which have also been detailed below:
- Europe Eye Care Market, By Product Type:
o Eyeglasses
o Contact Lens
o Intraocular Lens
o Eye Drops
o Others
- Europe Eye Care Market, By Coating:
o Anti-Glare
o Anti-Reflecting
o Others
- Europe Eye Care Market, By Lens Material:
o Normal Glass
o Polycarbonate
o Trivex
o Others
- Europe Eye Care Market, By Distribution Channel:
o Retail Stores
o E-Commerce
o Clinics
o Hospitals
- Europe Eye Care Market, By Country:
o Germany
o France
o United Kingdom
o Italy
o Spain
o Switzerland
o Netherlands
o Turkey
o Sweden
o Belgium
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Europe Eye Care Market.
Available Customizations:
Europe Eye Care market report with the given
market data, Tech Sci Research offers customizations according to a company's
specific needs. The following customization options are available for the
report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Europe Eye Care
Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected]